drugset / Trial / NCT00491491
Zevalin-beam for Aggressive Lymphoma
Phase 3
Completed
60 enrolled
Sheba Medical Center
Amsterdam UMC, location VUmc · collabCity of Hope Medical Center · collabUniversity of Göttingen · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.
Timeline
- Start
- 2007-06
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 0.4 unknown | — |